A CASE SERIES OF CHILDREN WITH HIGH-RISK METASTATIC NEUROBLASTOMA TREATED WITH A NOVEL TREATMENT STRATEGY CONSISTING OF POSTPONED PRIMARY SURGERY UNTIL THE END OF SYSTEMIC CHEMOTHERAPY INCLUDING HIGH-DOSE CHEMOTHERAPY

Yoshiko Hashii Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD,

Takeshi Kusafuka Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD,

Hideaki Ohta Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD,

Akihiro Yoneda Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD,

Yuko Osugi Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD,

Yasutsugu Kobayashi Department of Pathology, Osaka City General Hospital, Osaka, Japan

, MD, PhD,

Masahiro Fukuzawa Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD, &

Junichi Hara Departments of Pediatrics and Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

, MD, PhD show all

Abstract

The aim of this study was to clarify the feasibility of a novel treatment strategy consisting of postponed primary surgery till the end of systemic chemotherapy including HDC without interruption by local therapy for neuroblastoma patients at a high risk for relapse. After induction chemotherapy, patients received double conditioning HDC consisting of thiotepa and melphalan. Radical surgery was applied to local lesions. Irradiation was not applied to any lesions. Eleven consecutive pediatric neuroblastoma patients were treated according to this strategy. Seven of 11 patients remained in complete remission for 21–171 months. This treatment strategy seems feasible and a further study is warranted.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A CASE SERIES OF CHILDREN WITH HIGH-RISK METASTATIC NEUROBLASTOMA TREATED WITH A NOVEL TREATMENT STRATEGY CONSISTING OF POSTPONED PRIMARY SURGERY UNTIL THE END OF SYSTEMIC CHEMOTHERAPY INCLUDING HIGH-DOSE CHEMOTHERAPY

Information for

Open access

Opportunities

Help and information

A CASE SERIES OF CHILDREN WITH HIGH-RISK METASTATIC NEUROBLASTOMA TREATED WITH A NOVEL TREATMENT STRATEGY CONSISTING OF POSTPONED PRIMARY SURGERY UNTIL THE END OF SYSTEMIC CHEMOTHERAPY INCLUDING HIGH-DOSE CHEMOTHERAPY

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature